Experimental immunotherapy cures 100% of rectal cancer

There are clinical trials of the stimulant drug – then earlier this month there was an unprecedented news about a new experimental immunotherapy drug that has been 100% cured in patients being treated for colorectal cancer.

True, the study was small – only 14 people, but the doctor. Natalie Azar “Today”, “It’s 100% of patients. We never, ever talk about cancer treatment.”

The study, conducted at the Memorial Sloan Kettering (MSK) Cancer Center in New York City, was published in the New England Journal of Medicine.

All participants had stage 2 or 3 rectal adenocarcinoma. This means that their cancer has spread to the lymph nodes, but the tumor has not metastasized.

In addition, all patients had a rare specific mutation in the cancer, known as MMrd, which is considered to be particularly sensitive to chemotherapy.

Leave a Comment

Your email address will not be published.